These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 20726601)

  • 1. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
    J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
    Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
    Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule MDM2-p53 inhibitors: recent advances.
    Zhang B; Golding BT; Hardcastle IR
    Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    Zhao Y; Aguilar A; Bernard D; Wang S
    J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.
    Goyal S; Grover S; Dhanjal JK; Tyagi C; Goyal M; Grover A
    J Mol Graph Model; 2014 Jun; 51():64-72. PubMed ID: 24858256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QSAR models for isoindolinone-based p53-MDM2 interaction inhibitors using linear and non-linear statistical methods.
    Dong X; Yan J; Lu D; Wu P; Gao J; Liu T; Yang B; Hu Y
    Chem Biol Drug Des; 2012 May; 79(5):691-702. PubMed ID: 22233482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
    Ivanenkov YA; Vasilevski SV; Beloglazkina EK; Kukushkin ME; Machulkin AE; Veselov MS; Chufarova NV; Chernyaginab ES; Vanzcool AS; Zyk NV; Skvortsov DA; Khutornenko AA; Rusanov AL; Tonevitsky AG; Dontsova OA; Majouga AG
    Bioorg Med Chem Lett; 2015 Jan; 25(2):404-9. PubMed ID: 25479770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
    Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
    J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
    Xue X; Wei JL; Xu LL; Xi MY; Xu XL; Liu F; Guo XK; Wang L; Zhang XJ; Zhang MY; Lu MC; Sun HP; You QD
    J Chem Inf Model; 2013 Oct; 53(10):2715-29. PubMed ID: 24050442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
    Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors.
    Xue X; Bao G; Zhang HQ; Zhao NY; Sun Y; Zhang Y; Wang XL
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30513790
    [No Abstract]   [Full Text] [Related]  

  • 17. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
    Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR
    Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule inhibitors of the p53-MDM2.
    Hu CQ; Hu YZ
    Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.
    Azzarito V; Rowell P; Barnard A; Edwards TA; Macdonald A; Warriner SL; Wilson AJ
    Chembiochem; 2016 Apr; 17(8):768-73. PubMed ID: 26690307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.